Dean D Metcalfe

List of Publications by Year
in descending order

Version: 2024-02-01

169 papers	18,516 citations	13332 70 h-index	14012 133 g-index
170 all docs	170 docs citations	170 times ranked	12287 citing authors

#	Article	IF	Citations
1	The ingenious mast cell: Contemporary insights into mast cell behavior and function. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 83-99.	2.7	69
2	Defining baseline variability of serum tryptase levels improves accuracy in identifying anaphylaxis. Journal of Allergy and Clinical Immunology, 2022, 149, 1010-1017.e10.	1.5	38
3	Remission of indolent systemic mastocytosis in the absence of targeted therapy. Journal of Allergy and Clinical Immunology: in Practice, 2022, , .	2.0	0
4	Standards of Genetic Testing in the Diagnosis and Prognostication of Systemic Mastocytosis in 2022: Recommendations of the EU-US Cooperative Group. Journal of Allergy and Clinical Immunology: in Practice, 2022, 10, 1953-1963.	2.0	20
5	Personalized Management Strategies in Mast Cell Disorders: ECNM-AIM Userâ€™s Guide for Daily Clinical Practice. Journal of Allergy and Clinical Immunology: in Practice, 2022, 10, 1999-2012.e6.	2.0	35
6	Clinical impact and proposed application of molecular markers, genetic variants, and cytogenetic analysis in mast cell neoplasms: Status 2022. Journal of Allergy and Clinical Immunology, 2022, 149, 1855-1865.	1.5	19
7	Drug-induced mast cell eradication: AÂnovel approach to treat mast cell activation disorders?. Journal of Allergy and Clinical Immunology, 2022, 149, 1866-1874.	1.5	18
8	Acute increases in total serum tryptase unassociated with hemodynamic instability in diffuse cutaneous mastocytosis. Annals of Allergy, Asthma and Immunology, 2022, 129, 249-252.	0.5	2
9	Incorporating Tryptase Genotyping Into the Workup and Diagnosis of Mast Cell Diseases and Reactions. Journal of Allergy and Clinical Immunology: in Practice, 2022, 10, 1964-1973.	2.0	17
10	Heritable risk for severe anaphylaxis associated with increased Î±-tryptaseâ€“encoding germline copy number at TPSAB1. Journal of Allergy and Clinical Immunology, 2021, 147, 622-632.	1.5	137
11	A study of microbial translocation markers in mastocytosis. Clinical and Experimental Allergy, 2021, 51, 369-372.	1.4	1
12	A randomized double-blind, placebo-controlled study of omalizumab for idiopathic anaphylaxis. Journal of Allergy and Clinical Immunology, 2021, 147, 1004-1010.e2.	1.5	25
13	Emerging mechanisms contributing to mast cell-mediated pathophysiology with therapeutic implications. , 2021, 220, 107718.		32
14	Clinical Impact of Inherited and Acquired Genetic Variants in Mastocytosis. International Journal of Molecular Sciences, 2021, 22, 411.	1.8	21
15	Mastocytosis-derived extracellular vesicles deliver miR-23a and miR-30a into pre-osteoblasts and prevent osteoblastogenesis and bone formation. Nature Communications, 2021, 12, 2527.	5.8	38
16	Selecting the Right Criteria and Proper Classification to Diagnose Mast Cell Activation Syndromes: A Critical Review. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 3918-3928.	2.0	33
17	COVID-19 Vaccination in Mastocytosis: Recommendations of the European Competence Network on Mastocytosis (ECNM) and American Initiative in Mast Cell Diseases (AIM). Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 2139-2144.	2.0	31
18	Expression of MRGPRX2 in skin mast cells of patients with maculopapular cutaneous mastocytosis. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 3841-3843.e1.	2.0	16

#	Article	IF	Citations
19	Assessment of Osteoporosis and Fracture Risk in Mastocytosis within a North American Cohort. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 4459-4467.e10.	2.0	6
20	Decoding the intricacies of the mast cell compartment. British Journal of Haematology, 2021, , .	1.2	2
21	Clinical relevance of inherited genetic differences in human tryptases. Annals of Allergy, Asthma and Immunology, 2021, 127, 638-647.	0.5	30
22	Demonstration and implications of IL-3 upregulation of CD25 expression on human mast cells. Journal of Allergy and Clinical Immunology, 2021, , .	1.5	1
23	Updated Diagnostic Criteria and Classification of Mast Cell Disorders: A Consensus Proposal. HemaSphere, 2021, 5, e646.	1.2	128
24	Oncogenic D816V-KIT signaling in mast cells causes persistent IL-6 production. Haematologica, 2020, 105, 124-135.	1.7	26
25	Skewed Lymphocyte Subpopulations and Associated Phenotypes in Patients with Mastocytosis. Journal of Allergy and Clinical Immunology: in Practice, 2020, 8, 292-301.e2.	2.0	5
26	Targeting Mast Cells with Biologics. Immunology and Allergy Clinics of North America, 2020, 40, 667-685.	0.7	14
27	Diagnosis, Classification and Management of Mast Cell Activation Syndromes (MCAS) in the Era of Personalized Medicine. International Journal of Molecular Sciences, 2020, 21, 9030.	1.8	56
28	Mast cells as a unique hematopoietic lineage and cell system: From Paul Ehrlich's visions to precision medicine concepts. Theranostics, 2020, 10, 10743-10768.	4.6	107
29	Risk and management of patients with mastocytosis and MCAS in the SARS-CoV-2 (COVID-19) pandemic: Expert opinions. Journal of Allergy and Clinical Immunology, 2020, 146, 300-306.	1.5	23
30	Critical Signaling Events in the Mechanoactivation of Human Mast Cells through p.C492Y-ADGRE2. Journal of Investigative Dermatology, 2020, 140, 2210-2220.e5.	0.3	23
31	History and Current Status of Mastocytosis Research in the European Competence Network on Mastocytosis. , 2020, , 287-299.		0
32	Elevation in histamine and tryptase following exercise in patients with mastocytosis. Journal of Allergy and Clinical Immunology: in Practice, 2019, 7, 1310-1313.e2.	2.0	3
33	Maculopapular Cutaneous Mastocytosis in a Diverse Population. Journal of Allergy and Clinical Immunology: in Practice, 2019, 7, 2845-2847.	2.0	1
34	Impact of naturally forming human Î±/Î²-tryptase heterotetramers in the pathogenesis of hereditary Î±-tryptasemia. Journal of Experimental Medicine, 2019, 216, 2348-2361.	4.2	85
35	Why the 20% + 2 Tryptase Formula Is a Diagnostic Gold Standard for Severe Systemic Mast Cell Activation and Mast Cell Activation Syndrome. International Archives of Allergy and Immunology, 2019, 180, 44-51.	0.9	87
36	Description and Characterization of a Novel Human Mast Cell Line for Scientific Study. International Journal of Molecular Sciences, 2019, 20, 5520.	1.8	23

#	Article	IF	Citations
37	Proposed Diagnostic Algorithm for Patients with Suspected Mast Cell Activation Syndrome. Journal of Allergy and Clinical Immunology: in Practice, 2019, 7, 1125-1133.e1.	2.0	150
38	Inhibition of Allergic Reactivity through Targeting FcÎµRI-Bound IgE with Humanized Low-Affinity Antibodies. Journal of Immunology, 2019, 203, 2777-2790.	0.4	4
39	Aldh2 Attenuates Stem Cell Factor/Kit-Dependent Signaling and Activation in Mast Cells. International Journal of Molecular Sciences, 2019, 20, 6216.	1.8	3
40	Twelve-year follow-up of omalizumab therapy for anaphylaxis in 2 patients with systemic mastocytosis. Journal of Allergy and Clinical Immunology: in Practice, 2019, 7, 1314-1316.	2.0	19
41	Adverse reactions to drugs and biologics in patients with clonal mast cell disorders: AÂWork Group Report of the Mast Cells Disorder Committee, American Academy of Allergy, Asthma & Immunology. Journal of Allergy and Clinical Immunology, 2019, 143, 880-893.	1.5	50
42	Sialic acidâ€“binding immunoglobulin-like lectin (Siglec) 8 in patients with eosinophilic disorders: Receptor expression and targeting using chimeric antibodies. Journal of Allergy and Clinical Immunology, 2019, 143, 2227-2237.e10.	1.5	50
43	Reply. Journal of Allergy and Clinical Immunology, 2019, 143, 451-452.	1.5	1
44	A personal perspective on mentoring. Journal of Allergy and Clinical Immunology, 2019, 143, 548-549.	1.5	5
45	Mast cells signal their importance in health and disease. Journal of Allergy and Clinical Immunology, 2018, 142, 381-393.	1.5	169
46	A distinct biomolecular profile identifies monoclonal mast cell disorders in patients with idiopathic anaphylaxis. Journal of Allergy and Clinical Immunology, 2018, 141, 180-188.e3.	1.5	70
47	Interaction of DJ-1 with Lyn is essential for IgE-mediated stimulation of human mast cells. Journal of Allergy and Clinical Immunology, 2018, 142, 195-206.e8.	1.5	7
48	Chromogranin A is not a biomarker of mastocytosis. Journal of Allergy and Clinical Immunology: in Practice, 2018, 6, 687-689.e4.	2.0	8
49	Detection of KIT D816V in peripheral blood of children withÂmanifestations of cutaneous mastocytosis suggests systemic disease. British Journal of Haematology, 2018, 183, 775-782.	1.2	34
50	Mastocytosis-derived extracellular vesicles exhibit a mast cell signature, transfer KIT to stellate cells, and promote their activation. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E10692-E10701.	3.3	34
51	S1P4 Regulates Passive Systemic Anaphylaxis in Mice but Is Dispensable for Canonical IgE-Mediated Responses in Mast Cells. International Journal of Molecular Sciences, 2018, 19, 1279.	1.8	12
52	Targeting Sphingosine Kinase Isoforms Effectively Reduces Growth and Survival of Neoplastic Mast Cells With D816V-KIT. Frontiers in Immunology, 2018, 9, 631.	2.2	8
53	Preclinical human models and emerging therapeutics for advanced systemic mastocytosis. Haematologica, 2018, 103, 1760-1771.	1.7	18
54	Pathogenesis and Pathology of Mastocytosis. Annual Review of Pathology: Mechanisms of Disease, 2017, 12, 487-514.	9.6	49

#	Article	IF	Citations
55	Advances in the Classification and Treatment of Mastocytosis: Current Status and Outlook toward the Future. Cancer Research, 2017, 77, 1261-1270.	0.4	210
56	An optimized protocol for the generation and functional analysis of human mast cells from CD34 + enriched cell populations. Journal of Immunological Methods, 2017, 448, 105-111.	0.6	28
57	Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts. Blood, 2017, 129, 1420-1427.	0.6	520
58	Regulation of Reactive Oxygen Species and the Antioxidant Protein DJ-1 in Mastocytosis. PLoS ONE, 2016, 11, e0162831.	1.1	9
59	Consensus Opinion on Allogeneic Hematopoietic Cell Transplantation in Advanced Systemic Mastocytosis. Biology of Blood and Marrow Transplantation, 2016, 22, 1348-1356.	2.0	76
60	Elevated basal serum tryptase identifies a multisystem disorder associated with increased TPSAB1 copy number. Nature Genetics, 2016, 48, 1564-1569.	9.4	279
61	IL-6 promotes an increase in human mast cell numbers and reactivity through suppression of suppressor of cytokine signaling 3. Journal of Allergy and Clinical Immunology, 2016, 137, 1863-1871.e6.	1.5	86
62	Vibratory Urticaria Associated with a Missense Variant inADGRE2. New England Journal of Medicine, 2016, 374, 656-663.	13.9	157
63	Cutaneous manifestations in patients with mastocytosis: Consensus report of the European Competence Network on Mastocytosis; the American Academy of Allergy, Asthma & Immunology; and the European Academy of Allergology and Clinical Immunology. Journal of Allergy and Clinical Immunology, 2016, 137, 35-45.	1.5	289
64	Distinct transcriptome profiles differentiate nonsteroidal anti-inflammatory drugâ€“dependent from nonsteroidal anti-inflammatory drugâ€“independent food-induced anaphylaxis. Journal of Allergy and Clinical Immunology, 2016, 137, 137-146.	1.5	31
65	Impulse oscillometry identifies peripheral airway dysfunction in children with adenosine deaminase deficiency. Orphanet Journal of Rare Diseases, 2015, 10, 159.	1.2	10
66	Activated mast cells synthesize and release soluble ST2â€a decoy receptor for ILâ€33. European Journal of Immunology, 2015, 45, 3034-3044.	1.6	72
67	Interferonâ€Î³ enhances both the antiâ€bacterial and the proâ€inflammatory response of human mast cells to Staphylococcus aureus. Immunology, 2015, 146, 470-485.	2.0	23
68	Anaphylaxisâ€”a practice parameter update 2015. Annals of Allergy, Asthma and Immunology, 2015, 115, 341-384.	0.5	381
69	Growth of Human Mast Cells from Bone Marrow and Peripheral Blood-Derived CD34+ Pluripotent Hematopoietic Cells. Methods in Molecular Biology, 2015, 1220, 155-162.	0.4	14
70	Functional Deregulation of KIT. Immunology and Allergy Clinics of North America, 2014, 34, 219-237.	0.7	81
71	Mastocytosis associated with a rare germline KIT K509I mutation displays a well-differentiated mast cell phenotype. Journal of Allergy and Clinical Immunology, 2014, 134, 178-187.e1.	1.5	38
72	A Truncated Splice-Variant of the FcÎµRIÎ² Receptor Subunit Is Critical for Microtubule Formation and Degranulation in Mast Cells. Immunity, 2013, 38, 906-917.	6.6	43

#	Article	IF	Citations
73	KIT GNNK splice variants: Expression in systemic mastocytosis and influence on the activating potential of the D816V mutation in mast cells. Experimental Hematology, 2013, 41, 870-881.e2.	0.2	17
74	International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) & European Competence Network on Mastocytosis (ECNM) consensus response criteria in advanced systemic mastocytosis. Blood, 2013, 121, 2393-2401.	0.6	122
75	Mast cells, basophils, and mastocytosis. , 2013, , 284-297.		3
76	Systemic mastocytosis. , 2012, , 369-378.		0
77	Providing the TORC for cell cycle progression in neoplastic mast cells. Cell Cycle, 2012, 11, 210-211.	1.3	1
78	Definitions, Criteria and Global Classification of Mast Cell Disorders with Special Reference to Mast Cell Activation Syndromes: A Consensus Proposal. International Archives of Allergy and Immunology, 2012, 157, 215-225.	0.9	513
79	Stem Cell Factor Programs the Mast Cell Activation Phenotype. Journal of Immunology, 2012, 188, 5428-5437.	0.4	90
80	Cold Urticaria, Immunodeficiency, and Autoimmunity Related toPLCG2Deletions. New England Journal of Medicine, 2012, 366, 330-338.	13.9	391
81	Impulse oscillometry in the evaluation of diseases of the airways in children. Annals of Allergy, Asthma and Immunology, 2011, 106, 191-199.	0.5	159
82	mTORC1 and mTORC2 differentially regulate homeostasis of neoplastic and non-neoplastic human mast cells. Blood, 2011, 118, 6803-6813.	0.6	48
83	Clonal analysis of NRAS activating mutations in KIT-D816V systemic mastocytosis. Haematologica, 2011, 96, 459-463.	1.7	86
84	Glycogen Synthase Kinase-3Î² Is a Prosurvival Signal for the Maintenance of Human Mast Cell Homeostasis. Journal of Immunology, 2011, 187, 5587-5595.	0.4	13
85	Mastocytosis. Chemical Immunology and Allergy, 2010, 95, 110-124.	1.7	50
86	Btk-dependent Rac activation and actin rearrangement following FcÎµRI aggregation promotes enhanced chemotactic responses of mast cells. Journal of Cell Science, 2010, 123, 2576-2585.	1.2	78
87	CD72 Negatively Regulates KIT-Mediated Responses in Human Mast Cells. Journal of Immunology, 2010, 184, 2468-2475.	0.4	47
88	Glycogen Synthase Kinase 3Î² Activation Is a Prerequisite Signal for Cytokine Production and Chemotaxis in Human Mast Cells. Journal of Immunology, 2010, 184, 564-572.	0.4	21
89	Mast cell activation syndrome: Proposed diagnostic criteria. Journal of Allergy and Clinical Immunology, 2010, 126, 1099-1104.e4.	1.5	266
90	IgE, mast cells, basophils, and eosinophils. Journal of Allergy and Clinical Immunology, 2010, 125, S73-S80.	1.5	1,065

#	Article	IF	Citations
91	Mast Cell Precursors and Signaling Pathways. , 2010, , 283-295.		0
92	IgE-FcÎµRI Interactions Determine HIV Coreceptor Usage and Susceptibility to Infection during Ontogeny of Mast Cells. Journal of Immunology, 2009, 182, 6401-6409.	0.4	24
93	Amplification mechanisms for the enhancement of antigen-mediated mast cell activation. Immunologic Research, 2009, 43, 15-24.	1.3	42
94	Assessing anaphylactic risk? Consider mast cell clonality. Journal of Allergy and Clinical Immunology, 2009, 123, 687-688.	1.5	53
95	Mechanisms of mast cell signaling in anaphylaxis. Journal of Allergy and Clinical Immunology, 2009, 124, 639-646.	1.5	240
96	Kit- and FcÉ›RI-induced differential phosphorylation of the transmembrane adaptor molecule NTAL/LAB/LAT2 allows flexibility in its scaffolding function in mast cells. Cellular Signalling, 2008, 20, 195-205.	1.7	64
97	Synergistic activation of phospholipases CÎ³ and CÎ²: A novel mechanism for PI3K-independent enhancement of FcÎµRI-induced mast cell mediator release. Cellular Signalling, 2008, 20, 625-636.	1.7	55
98	The Phosphoinositide 3-Kinase-Dependent Activation of Btk Is Required for Optimal Eicosanoid Production and Generation of Reactive Oxygen Species in Antigen-Stimulated Mast Cells. Journal of Immunology, 2008, 181, 7706-7712.	0.4	66
99	Activation and Function of the mTORC1 Pathway in Mast Cells. Journal of Immunology, 2008, 180, 4586-4595.	0.4	112
100	Concurrent Inhibition of Kit- and FcÏµRI-Mediated Signaling: Coordinated Suppression of Mast Cell Activation. Journal of Pharmacology and Experimental Therapeutics, 2008, 324, 128-138.	1.3	40
101	Mast cells and mastocytosis. Blood, 2008, 112, 946-956.	0.6	481
102	Activity of imatinib in systemic mastocytosis with chronic basophilic leukemia and a PRKG2-PDGFRB fusion. Haematologica, 2008, 93, 49-56.	1.7	42
103	Understanding the mechanisms of anaphylaxis. Current Opinion in Allergy and Clinical Immunology, 2008, 8, 310-315.	1.1	158
104	FcÎµRI- and FcÎ³ Receptor-Mediated Production of Reactive Oxygen Species by Mast Cells Is Lipoxygenase- and Cyclooxygenase-Dependent and NADPH Oxidase-Independent. Journal of Immunology, 2007, 179, 7059-7071.	0.4	45
105	Effects of Gamma Radiation on FcÎµRI and TLR-Mediated Mast Cell Activation. Journal of Immunology, 2007, 179, 3276-3286.	0.4	46
106	Silica-Directed Mast Cell Activation Is Enhanced by Scavenger Receptors. American Journal of Respiratory Cell and Molecular Biology, 2007, 36, 43-52.	1.4	92
107	Targeting Kit Activation: A Potential Therapeutic Approach in the Treatment of Allergic Inflammation. Inflammation and Allergy: Drug Targets, 2007, 6, 57-62.	1.8	36
108	Demonstration of an aberrant mast-cell population with clonal markers in a subset of patients with â€œidiopathicâ€•anaphylaxis. Blood, 2007, 110, 2331-2333.	0.6	208

#	Article	IF	Citations
109	Human tissue mast cells are an inducible reservoir of persistent HIV infection. Blood, 2007, 109, 5293-5300.	0.6	87
110	Human mast cells are capable of serotonin synthesis and release. Journal of Allergy and Clinical Immunology, 2007, 119, 498-499.	1.5	163
111	KIT D816Vâ€“associated systemic mastocytosis with eosinophilia and FIP1L1/PDGFRA-associated chronic eosinophilic leukemia are distinct entities. Journal of Allergy and Clinical Immunology, 2007, 120, 680-687.	1.5	105
112	Mast cells, which interact withEscherichia coli, up-regulate genes associated with innate immunity and become less responsive to FcÎµRI-mediated activation. Journal of Leukocyte Biology, 2006, 79, 339-350.	1.5	35
113	High-resolution tracking of cell division demonstrates differential effects of TH1 and TH2 cytokines on SCF-dependent human mast cell production in vitro:correlation with apoptosis and Kit expression. Blood, 2005, 105, 592-599.	0.6	41
114	Genetically modified crops and allergenicity. Nature Immunology, 2005, 6, 857-860.	7.0	24
115	Thrombopoietin alone or in the presence of stem cell factor supports the growth of KIT(CD117)low/ MPL(CD110)+ human mast cells from hematopoietic progenitor cells. Experimental Hematology, 2005, 33, 413-421.	0.2	21
116	Btk Plays a Crucial Role in the Amplification of FcÏµRI-mediated Mast Cell Activation by Kit. Journal of Biological Chemistry, 2005, 280, 40261-40270.	1.6	93
117	Mastocytosis: Pathology, genetics, and current options for therapy. Leukemia and Lymphoma, 2005, 46, 35-48.	0.6	180
118	Analysis of the lineage relationship between mast cells and basophils using the c-kit D816V mutation as a biologic signature. Journal of Allergy and Clinical Immunology, 2005, 115, 1155-1161.	1.5	42
119	Regulation of normal and neoplastic human mast cell development in mastocytosis. Transactions of the American Clinical and Climatological Association, 2005, 116, 185-203; discussion 203-4.	0.9	15
120	Rodent and Human Mast Cells Produce Functionally Significant Intracellular Reactive Oxygen Species but Not Nitric Oxide. Journal of Biological Chemistry, 2004, 279, 48751-48759.	1.6	95
121	The biology of Kit in disease and the application of pharmacogenetics. Journal of Allergy and Clinical Immunology, 2004, 114, 13-19.	1.5	120
122	Activation of human mast cells by aggregated IgG through FcÎ³RI: additive effects of C3a. Clinical Immunology, 2004, 110, 172-180.	1.4	109
123	Activation of mast cells by double-stranded RNA: evidence for activation through Toll-like receptor 3. Journal of Allergy and Clinical Immunology, 2004, 114, 174-182.	1.5	314
124	17-Allylamino-17-demethoxygeldanamycin (17-AAG) is effective in down-regulating mutated, constitutively activated KIT protein in human mast cells. Blood, 2004, 103, 1078-1084.	0.6	147
125	NTAL phosphorylation is a pivotal link between the signaling cascades leading to human mast cell degranulation following Kit activation and FcÂRI aggregation. Blood, 2004, 104, 207-214.	0.6	117
126	A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib. Blood, 2004, 103, 3222-3225.	0.6	336

#	Article	IF	Citations
127	Kit and FcÏµRI mediate unique and convergent signals for release of inflammatory mediators from human mast cells. Blood, 2004, 104, 2410-2417.	0.6	144
128	Effects of tyrosine kinase inhibitor STI571 on human mast cells bearing wild-type or mutated c-kit. Experimental Hematology, 2003, 31, 686-692.	0.2	213
129	Comparison of FcÎµRI- and FcÎ³RI-mediated degranulation and TNF-Î± synthesis in human mast cells: selective utilization of phosphatidylinositol-3-kinase for FcÎ³RI-induced degranulation. European Journal of Immunology, 2003, 33, 1450-1459.	1.6	56
130	Aggressive systemic mastocytosis and related mast cell disorders: current treatment options and proposed response criteria. Leukemia Research, 2003, 27, 635-641.	0.4	217
131	Characterization of novel stem cell factor responsive human mast cell lines LAD 1 and 2 established from a patient with mast cell sarcoma/leukemia; activation following aggregation of FcÎµRI or FcÎ³RI. Leukemia Research, 2003, 27, 677-682.	0.4	473
132	Functional and phenotypic studies of two variants of a human mast cell line with a distinct set of mutations in the c-kit proto-oncogene. Immunology, 2003, 108, 89-97.	2.0	105
133	Diagnosis and treatment of systemic mastocytosis: state of the art. British Journal of Haematology, 2003, 122, 695-717.	1.2	187
134	Assessment of the extent of cutaneous involvement in children and adults with mastocytosis: Relationship to symptomatology, tryptase levels, and bone marrow pathology. Journal of the American Academy of Dermatology, 2003, 48, 508-516.	0.6	108
135	The Phospholipase CÎ³1-dependent Pathway of FcÏµRI-mediated Mast Cell Activation Is Regulated Independently of Phosphatidylinositol 3-Kinase. Journal of Biological Chemistry, 2003, 278, 48474-48484.	1.6	100
136	The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations. Blood, 2002, 99, 1741-1744.	0.6	416
137	Regression of Urticaria Pigmentosa in Adult Patients With Systemic Mastocytosis. Archives of Dermatology, 2002, 138, 785-90.	1.7	35
138	Levels of mast-cell growth factors in plasma and in suction skin blister fluid in adults with mastocytosis: Correlation with dermal mast-cell numbers and mast-cell tryptase. Journal of Allergy and Clinical Immunology, 2002, 109, 82-88.	1.5	52
139	Factors affecting the determination of threshold doses for allergenic foods: How much is too much?. Journal of Allergy and Clinical Immunology, 2002, 109, 24-30.	1.5	348
140	Determination of protein phosphorylation in FcÎµRI-activated human mast cells by immunoblot analysis requires protein extraction under denaturing conditions. Journal of Immunological Methods, 2002, 268, 239-243.	0.6	51
141	Association of the Q576R polymorphism in the interleukin-4 receptor Î± chain with indolent mastocytosis limited to the skin. Blood, 2001, 98, 880-882.	0.6	51
142	Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leukemia Research, 2001, 25, 603-625.	0.4	1,020
143	A Comparison of Mediators Released or Generated by IFN-Î³-Treated Human Mast Cells Following Aggregation of FcÎ³RI or FcÎµRI. Journal of Immunology, 2001, 166, 4705-4712.	0.4	101
144	Secretion of Interleukin-1 Receptor Antagonist from Human Mast Cells after Immunoglobulin Eâ€“Mediated Activation and after Segmental Antigen Challenge. American Journal of Respiratory Cell and Molecular Biology, 2001, 25, 685-691.	1.4	20

#	Article	IF	Citations
145	Mast cells in innate immunity. Immunological Reviews, 2000, 173, 131-140.	2.8	338
146	Expression of a Functional High-Affinity IgG Receptor, FcÎ³RI, on Human Mast Cells: Up-Regulation by IFN-Î³. Journal of Immunology, 2000, 164, 4332-4339.	0.4	176
147	Mast Cell Migratory Response to Interleukin-8 Is Mediated Through Interaction With Chemokine Receptor CXCR2/Interleukin-8RB. Blood, 1999, 93, 2791-2797.	0.6	93
148	Demonstration That Human Mast Cells Arise From a Progenitor Cell Population That Is CD34+, c-kit+, and Expresses Aminopeptidase N (CD13). Blood, 1999, 94, 2333-2342.	0.6	359
149	Frequency and characterization of antigen-specific IL-4â€“ and IL-13â€“ producing basophils and T cells in peripheral blood of healthy and asthmatic subjects. Journal of Allergy and Clinical Immunology, 1999, 104, 811-819.	1.5	112
150	Mast Cell Migratory Response to Interleukin-8 Is Mediated Through Interaction With Chemokine Receptor CXCR2/Interleukin-8RB. Blood, 1999, 93, 2791-2797.	0.6	20
151	Cytogenetic abnormalities and their lack of relationship to the Asp816Val c-kit mutation in the pathogenesis of mastocytosis. Journal of Allergy and Clinical Immunology, 1998, 102, 523-524.	1.5	21
152	Human mast cells express functional TrkA and are a source of nerve growth factor. European Journal of Immunology, 1997, 27, 2295-2301.	1.6	209
153	Assessment of the allergenic potential of foods derived from genetically engineered crop plants*. Critical Reviews in Food Science and Nutrition, 1996, 36, 165-186.	5.4	374
154	Treatment of Three Patients with Systemic Mastocytosis with Interferon Alpha-2b. Leukemia and Lymphoma, 1996, 22, 501-508.	0.6	83
155	The Role of c-Kit and Its Ligand, Stem Cell Factor, in Mast Cell Apoptosis. International Archives of Allergy and Immunology, 1995, 107, 136-138.	0.9	43
156	Mast cell ontogeny and apoptosis. Experimental Dermatology, 1995, 4, 227-230.	1.4	41
157	Radiotherapy of Refractory Bone Pain Due to Systemic Mast Cell Disease. American Journal of Clinical Oncology: Cancer Clinical Trials, 1994, 17, 328-330.	0.6	31
158	Seafood toxins. Clinical Reviews in Allergy, 1993, 11, 241-60.	1.0	8
159	Hematologic manifestations of systemic mast cell disease: A prospective study of laboratory and morphologic features and their relation to prognosis. American Journal of Medicine, 1991, 91, 612-624.	0.6	156
160	Immune mechanisms in food allergy. Clinical and Experimental Allergy, 1991, 21, 321-324.	1.4	54
161	Classification and Diagnosis of Mastocytosis: Current Status. Journal of Investigative Dermatology, 1991, 96, S2-S4.	0.3	307
162	Analysis of plasma histamine levels in patients with mast cell disorders. American Journal of Medicine, 1989, 87, 649-654.	0.6	73

#	Article	IF	Citations
163	Hematopathology of the Bone Marrow in Pediatric Cutaneous Mastocytosis: A Study of 17 Patients. American Journal of Clinical Pathology, 1989, 91, 558-562.	0.4	54
164	Demonstration and characterization of a transient arthritis in rats following sensitization of synovial mast cells with antigen-specific ige and parenteral challenge with specific antigen. Arthritis and Rheumatism, 1988, 31, 1063-1067.	6.7	23
165	Gastrointestinal Dysfunction in Systemic Mastocytosis. Gastroenterology, 1988, 95, 657-667.	0.6	141
166	Tryptase Levels as an Indicator of Mast-Cell Activation in Systemic Anaphylaxis and Mastocytosis. New England Journal of Medicine, 1987, 316, 1622-1626.	13.9	737
167	Mast cell numbers in rheumatoid synovial tissues. Arthritis and Rheumatism, 1987, 30, 130-137.	6.7	133
168	Food allergens. Clinical Reviews in Allergy, 1985, 3, 331-349.	1.0	53
169	Isolation and Characterization of Heparin from Human Lung. Journal of Clinical Investigation, 1979, 64, 1537-1543.	3.9	142